GET DAILY SIGNALSHyperfine (HYPR): Can Shares Reach the $2.00 Analyst Target From $0.73?
Key Takeaways
- The central target of $2.00 is the arithmetic mean of four verified, current analyst price targets, rounded from $2.025.
- The reviewed targets range from a low of $1.60 (B. Riley Securities) to a high of $2.50 (Lake Street), with all four analysts rating the stock a Buy.
- At a recent price near $0.73, reaching $2.00 would require a gain of about 174%, a very large move for any stock.
- The strongest support comes from accelerating revenue growth, expanding gross margins, new product launches, and regulatory clearances in international markets.
- The biggest risks are persistent net losses, negative cash flow, a small revenue base, insider selling, and a wide gap between the highest and lowest targets.
- For more detail on the company's Major News and Today's Price Move, along with a deeper Forecast and Earnings analysis, explore these dedicated pages.
- For automated trade ideas, explore Trending AI Robots, which scan markets for emerging patterns.
Analyst Price Targets and Consensus View
Four credible, current analyst price targets were reviewed, all carrying Buy ratings. BTIG (Marie Thibault) reiterated a Buy with a $2.00 target in October 2026; Lucid Capital initiated coverage with a Buy and a $2.00 target in late October 2026; Lake Street's Ryan Meyers reiterated a Buy with a $2.50 target in late September 2026; and B. Riley Securities maintained a Buy while lowering its target from $2.00 to $1.60 in August 2026.
The arithmetic mean of these four figures is $2.03, which rounds to the $2.00 central target used here. The range is wide — $1.60 to $2.50 — which reflects genuine disagreement about how quickly Hyperfine can scale its still-small revenue base. Analysts broadly frame the story around adoption of the Swoop portable MRI system, margin expansion, and international market entry, while differing on how aggressively to value early-stage growth. This average is a calculated figure, not an official published consensus, and it should not be read as a guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With shares near $0.73, the stock would need to more than double to reach the $2.00 central target, and even the lowest reviewed target of $1.60 implies upside of roughly 119%. That is a very large required move. Hyperfine's business is growing: full-year 2026 guidance calls for revenue of roughly $20 million to $22 million, which would represent growth of about 55%, with continued gross margin expansion. Analysts project revenue rising further toward roughly $26 million in 2027. However, the company remains unprofitable, with projected EPS (earnings per share) losses of about $0.34 in 2026, meaning the investment case rests on durable revenue growth and eventual operating leverage rather than current earnings.
What Could Support a Move Toward the Target
- Accelerating adoption: Quarterly revenue growth has reaccelerated, driven by the next-generation Swoop system and its Optive AI software.
- Margin improvement: Gross margin has risen toward the 50% range, supporting the path toward profitability.
- Geographic expansion: The company has launched in Europe and secured regulatory approval in India, broadening its addressable market.
- Growing clinical evidence: Peer-reviewed publications in journals such as Stroke and the Journal of Neurosurgery are building a clinical case for portable MRI.
- Index inclusion: Hyperfine joined the Russell 3000 and Russell 2000 indexes in mid-2026, potentially broadening institutional ownership.
What Could Prevent the Target From Being Reached
- Ongoing losses and cash burn: The company still reports GAAP (generally accepted accounting principles) net losses and negative free cash flow.
- Small revenue base: A roughly $20 million revenue run-rate leaves little room for execution missteps.
- Valuation and dilution risk: As a pre-profit small-cap, Hyperfine may need additional capital, which could dilute existing holders.
- Insider selling: Recent insider activity, including sales by the CFO, has leaned negative, which some investors read cautiously.
- Wide target dispersion: The gap between the $1.60 and $2.50 targets signals meaningful uncertainty about the pace and durability of growth.
Technical Levels and Market Structure
Hyperfine remains a low-priced, high-volatility stock, having traded well below the $2.00 level after a pullback from earlier highs. The $1.00 area represents a psychological and technical milestone that shares would need to reclaim before the higher targets come into view. The wide gap between the current price and the analyst range reflects both the stock's speculative character and its sensitivity to news flow around product adoption and regulatory developments.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of roughly 12 months, though firms differ in methodology and timing. Investors tracking this stock should watch quarterly revenue and guidance updates, gross margin trends, progress toward profitability, new regulatory clearances and market launches, the pace of Swoop system placements, and any additional insider transactions or capital raises. Analyst revisions in either direction can also move a thinly traded small-cap disproportionately.
Using AI Daily Buy/Sell Signals in My Process
Traders seeking an additional, data-driven lens on Hyperfine and thousands of other stocks and ETFs can turn to Tickeron's AI Daily Buy/Sell Signals. The platform uses artificial intelligence to continuously monitor changing market conditions, technical behavior, and AI-driven analysis, generating Buy, Sell, or Hold signals as conditions evolve. This can help traders discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. In my own work, I’ve found these signals useful for cross-checking manual analysis on smaller names like this one.
Final Assessment
The $2.00 central target reflects the average of four Buy-rated analyst price targets ranging from $1.60 to $2.50, and it sits roughly 174% above Hyperfine's recent price near $0.73. The bull case rests on accelerating adoption of the Swoop portable MRI platform, expanding gross margins, international growth, and growing clinical validation. The bear case centers on continued net losses, negative cash flow, a modest revenue base, insider selling, and the wide dispersion among analyst forecasts. Reaching $2.00 is a very large ask that would require sustained execution, but the analyst community has nevertheless placed its targets well above current levels. Investors should monitor revenue growth, margin trends, and regulatory milestones rather than treat the average target as a certainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HYPR sees its Stochastic Oscillator climbs out of oversold territory
On November 04, 2026, the Stochastic Oscillator for HYPR moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 71 instances where the indicator left the oversold zone. In 59 of the 71 cases the stock moved higher in the following days. This puts the odds of a move higher at over 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +8.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where HYPR advanced for three days, in 181 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HYPR as a result. In 93 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for HYPR turned negative on October 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
HYPR moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HYPR crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HYPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
HYPR broke above its upper Bollinger Band on October 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HYPR entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.076) is normal, around the industry mean (4.142). P/E Ratio (-1.945) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.340) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. HYPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HYPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement